Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.

Gordy, James T; Mazumdar, Kaushiki; Dutta, Noton K

Gordy, James T; Mazumdar, Kaushiki; Dutta, Noton K.

Affiliation

Gordy JT; The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Mazumdar K; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dutta NK; Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ndutta1@jhmi.edu.

Antimicrob Agents Chemother ; 64(8)2020 07 22.

Article in En | MEDLINE | ID: mdl-32423954

Subject(s)

Coronavirus Infections; Coronavirus; Pandemics; Pneumonia, Viral; Betacoronavirus; COVID-19; Drug Development; Humans; SARS-CoV-2

Key words

COVID-19; FDA-approved drugs; SARS-CoV-2; antiviral drugs; coronavirus disease 2019; host-directed therapy; pathogen-directed therapy; severe acute respiratory syndrome coronavirus-2; treatment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Coronavirus / Pandemics Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2020 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google